Non-Steroidal Anti-Inflammatory Drugs Market Analysis, Volume, Drivers and Opportunities Till 2025

Albany, NY -- (SBWIRE) -- 02/22/2018 -- Non-steroidal anti-inflammatory drugs (NSAIDs) is a class of powerful analgesics, distinguished by their non-steroidal chemical structure. These drugs are frequently prescribed to reduce pain caused due to inflammation. These are considered the first line of treatment in pain management due to three basic properties: analgesic, antipyretic, and anti-inflammatory. Usage of non-steroidal anti-inflammatory drugs in pain management dates back to the 1960s and 1970s when the first few key molecules such as diclofenac and ibuprofen were approved by the U.S. FDA. The patents for all (except one) the key branded formulations in this market have expired, rendering the market completely generic and even over-the-counter (OTC) for some drugs. The most common OTC drugs in this class include aspirin and ibuprofen used in the treatment of headache, body ache, sports injuries, and menstrual cramps. Non-steroidal anti-inflammatory drugs are categorized into various groups: salicylates (diflunisal, salsalate, and acetylsalicylic acid), acetic acid derivatives (diclofenac, ketorolac, indomethacin, and etodolac), selective COX-2 inhibitors (celecoxib), proprionic acid derivatives (ibuprofen, naproxen, ketoprofen, and fenoprofen), fenamic acid derivatives (meclofenamic acid, tolfenamic acid, and mefenamic acid), and enolic acid derivatives (oxicam, piroxicam, tenoxicam and lornoxicam).